Two RNA biotechs, ADARx Pharmaceuticals and City Therapeutics, are taking advantage of the IPO frenzy, which has led to a total of 27 newly public biotechs so far this year.
ADARx raises $446M in biotech’s third largest IPO of 2026, City files to go public